DRUG SAFETY
Scope & Guideline
Elevating Standards in Pharmacological Research
Introduction
Aims and Scopes
- Pharmacovigilance and Drug Safety Monitoring:
This area covers the systematic collection, analysis, and interpretation of data related to adverse drug reactions (ADRs) and other drug-related problems. It aims to improve safety and efficacy in drug use through ongoing monitoring. - Risk Assessment and Management:
Research focusing on identifying, assessing, and managing risks associated with drug therapies, including the development of frameworks for safer medication use in various populations. - Real-World Evidence and Data Analysis:
Utilizing real-world data sources to analyze drug safety outcomes, effectiveness, and patterns of drug usage. This includes studies using electronic health records and spontaneous reporting systems. - Methodological Innovations in Drug Safety Research:
Development of new methodologies and technologies (e.g., machine learning, big data analytics) for signal detection and causal inference in pharmacovigilance. - Patient-Centric Approaches to Drug Safety:
Research that emphasizes the role of patients in pharmacovigilance, including patient-reported outcomes and experiences related to drug safety. - Special Populations and Vulnerable Groups:
Studies focusing on drug safety in specific populations, such as pregnant women, children, and the elderly, to address unique safety concerns and ensure tailored risk management.
Trending and Emerging
- Integration of Artificial Intelligence and Machine Learning:
There is a growing emphasis on the use of AI and machine learning technologies in pharmacovigilance for signal detection, data analysis, and improving reporting accuracy. - Focus on Vaccine Safety and Monitoring:
Following the COVID-19 pandemic, there has been a significant increase in research related to vaccine safety, particularly regarding the monitoring of adverse events associated with COVID-19 vaccinations. - Patient Engagement and Involvement:
Emerging research emphasizes the importance of involving patients in pharmacovigilance processes, including patient-reported outcomes and experiences, to enhance drug safety practices. - Real-World Data Utilization:
The use of real-world data for evaluating drug safety and efficacy is trending, with studies focusing on how these data can inform regulatory decisions and clinical practice. - Polypharmacy and Drug-Drug Interaction Studies:
Research addressing the complexities of polypharmacy and drug-drug interactions is gaining prominence, reflecting the need to understand safety in patients taking multiple medications. - Ethical Considerations in Pharmacovigilance:
Emerging discussions around the ethical implications of pharmacovigilance practices, particularly regarding data privacy and the responsibilities of stakeholders in drug safety.
Declining or Waning
- Traditional Pharmacovigilance Methods:
There is a noticeable decline in the publication of papers focusing solely on traditional pharmacovigilance methods, as newer technologies and data sources are increasingly prioritized. - General Drug Safety Studies Without Specific Contexts:
Research that lacks a specific context or fails to address contemporary issues in drug safety may be receiving less attention, as the emphasis shifts towards studies that are more relevant to current healthcare challenges. - Single-Agent Drug Studies:
Studies focusing solely on the safety of single agents without considering polypharmacy or drug-drug interactions are becoming less prominent, reflecting a broader understanding of the complexities of real-world medication use. - Pharmacovigilance in Low-Resource Settings:
While still important, the specific focus on pharmacovigilance in low-resource settings may be waning as the journal expands its scope to include more global and comprehensive approaches.
Similar Journals
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Connecting Researchers with Cutting-Edge Drug DiscoveriesBritish Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.
PHARMAZIE
Advancing pharmaceutical knowledge since 1947.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.
Drug Healthcare and Patient Safety
Fostering global discourse on drug healthcare advancements.Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.
Therapeutic Advances in Drug Safety
Empowering Global Health through Drug Safety InnovationTherapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.
Therapeutics and Clinical Risk Management
Championing open access to critical therapeutic knowledge.Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.
DRUGS & THERAPY PERSPECTIVES
Bridging Research and Clinical Practice for Better OutcomesDRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.
Ars Pharmaceutica
Championing excellence in pharmaceutical research and innovation.Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.
International Journal of Pharmacology
Bridging Research and Application in PharmacologyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
BMC Pharmacology & Toxicology
Advancing knowledge in pharmacology and toxicology.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.